CLINICAL_TRIALS
trial_result
· 2018-06-08
Clinical Trial Update: Efficacy Study of CYT997 in Multiple Myeloma [Phase 2]
Summary
A Phase 2 efficacy trial of CYT997 in relapsed and refractory multiple myeloma has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Gilead Sciences | Conditions: Relapsed and Refractory Multiple Myeloma | Phase 2 | Status: TERMINATED